Immunovant
IMVT
Immunovant (IMVT) earnings history
Most recent quarter
- Fiscal period
- Q1 2027
- Period end
- Jun 30, 2026
- EPS actual
- −$0.75
- EPS estimate
- −$0.63
- EPS surprise
- −19.26%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2027 | Aug 6, 2026 | −$0.63 | −$0.75 | −19.26% | $0.00 | SEC |
| Q4 2026 | May 20, 2026 | −$0.59 | −$0.73 | −23.31% | $0.00 | SEC |
| Q3 2026 | Feb 6, 2026 | −$0.71 | −$0.61 | +14.49% | $0.00 | SEC |
| Q2 2026 | Nov 10, 2025 | −$0.71 | −$0.73 | −2.21% | $0.00 | SEC |
| Q1 2026 | Aug 11, 2025 | −$0.68 | −$0.71 | −4.35% | $0.00 | SEC |
| Q4 2025 | May 29, 2025 | −$0.71 | −$0.64 | +10.28% | $0.00 | SEC |
| Q3 2025 | Feb 6, 2025 | −$0.75 | −$0.76 | −1.10% | $0.00 | SEC |
| Q2 2025 | Nov 7, 2024 | −$0.60 | −$0.74 | −23.29% | $0.00 | SEC |
| Q1 2025 | Aug 6, 2024 | −$0.53 | −$0.60 | −13.08% | $0.00 | SEC |
| Q4 2024 | May 29, 2024 | −$0.43 | −$0.52 | −21.04% | $0.00 | SEC |
| Q3 2024 | Feb 12, 2024 | −$0.43 | −$0.29 | +32.35% | $0.00 | SEC |
| Q2 2024 | Nov 9, 2023 | −$0.46 | −$0.45 | +1.77% | $0.00 | SEC |
| Q1 2024 | Aug 10, 2023 | −$0.45 | −$0.57 | −27.72% | $0.00 | SEC |
| Q4 2023 | May 22, 2023 | −$0.42 | −$0.46 | −8.80% | $0.00 | SEC |
| Q3 2023 | Feb 3, 2023 | −$0.37 | −$0.49 | −31.33% | $0.00 | SEC |
| Q2 2023 | Nov 4, 2022 | −$0.37 | −$0.41 | −10.78% | $0.00 | SEC |
| Q1 2023 | Aug 5, 2022 | −$0.37 | −$0.35 | +6.54% | $0.00 | SEC |
| Q4 2022 | Jun 8, 2022 | −$0.36 | −$0.41 | −13.35% | $0.00 | SEC |
| Q3 2022 | Feb 4, 2022 | −$0.32 | −$0.36 | −12.92% | $0.00 | SEC |
| Q2 2022 | Nov 5, 2021 | −$0.26 | −$0.35 | −33.13% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Immunovant (IMVT) last report earnings?
Immunovant last reported on Aug 6, 2026, covering fiscal Q1 2027.
Did IMVT beat earnings estimates?
No. Immunovant reported EPS of −$0.75 for Q1 2027 against a −$0.63 estimate — a 19.26% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.